Expert perspectives on cholangiocarcinoma (CCA)

Cholangiocarcinoma: The little-known, rare cancer of the biliary tract (ESMO 2022)

Professor Filippo de Braud

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Università degli Studi di Milano, Milan, Italy

Disclosures

Professor Filippo de Braud:

Company/Organisation	Relationship(s)
AstraZeneca, BMS, EMD Serono, Incyte, Menarini, MSD, Nerviano Medical Science, Novartis, Pierre Fabre, Roche, Sanofi	Consultant/advisory board
Amgen, BMS, Dephaforum, Healthcare Research & Pharmacoepidemiology, Incyte, Merck KGAA, MSD, Pfizer, Roche, Sanofi, Seagen, Servier	Speaker
Basilea Pharmaceutica International AG, BMS, Daiichi Sankyo, Exelixis, Roche, Ignyta Operating, Janssen, Kymab, LOXO Oncology, MedImmune, Merck KGAA, Merck Sharp & Dohme Italia Spa, MSD, Novartis, Pfizer, Tesaro	Principal investigator

This website has been created and funded by Incyte.

If you would like to request further medical information, please visit:
www.incyteglobalmedicalinformation.com